Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%
Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price shot up 7.4% during trading on Tuesday . The stock traded as high as $18.79 and last traded at $18.73. 7,198 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 235,939 shares. The stock had previously closed at $17.44.
Prime Medicine,Inc.(NYSEArca:PRME-GET Rating)股價週二大漲7.4%,盤中一度漲至18.79美元,最新報18.73美元。午盤時有7,198股易手,較235,939股的平均成交量下跌97%。該股此前收盤報17.44美元。
Analyst Ratings Changes
分析師評級發生變化
Several research firms have commented on PRME. The Goldman Sachs Group began coverage on shares of Prime Medicine in a research note on Monday, November 14th. They issued a "neutral" rating and a $22.00 price target for the company. Jefferies Financial Group began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set a "buy" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "overweight" rating and a $27.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "equal weight" rating and a $23.00 price objective for the company.
幾家研究公司對PRME發表了評論。11月14日,週一,高盛在一份研究報告中開始對優質醫藥的股票進行報道。他們對該公司的評級為“中性”,目標價為22.00美元。傑富瑞金融集團於11月14日(星期一)在一份研究報告中開始報道Prime Medicine的股票。他們為該公司設定了“買入”評級和25.00美元的目標價。摩根大通公司在11月14日星期一的一份研究報告中開始對Prime Medicine的股票進行報道。他們為該公司設定了“增持”評級和27.00美元的目標價。最後,摩根士丹利在11月14日星期一的一份研究報告中開始了對優質醫藥股票的報道。他們為該公司設定了“同等權重”的評級和23.00美元的目標價。
Prime Medicine Stock Down 0.8 %
Prime Medicine股價下跌0.8%
The business's fifty day moving average price is $19.27 and its 200 day moving average price is $19.89.
該業務的50日移動均線價格為19.27美元,200日移動均線價格為19.89美元。
Insider Transactions at Prime Medicine
Prime Medicine的內幕交易
Prime Medicine Company Profile
優質醫藥公司簡介
(Get Rating)
(獲取評級)
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Prime Medicine,Inc.是一家生物技術公司,通過部署基因編輯技術提供基因療法來治療疾病。它為Prime Edants提供了Prime Editor蛋白質和pegRNA,前者包括CaS蛋白質和逆轉錄酶之間的融合;後者將Prime Editing定位於特定的基因組位置,並提供對目標DNA序列進行所需編輯的模板。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- Santa Claus Rally? Here's What Needs to Happen
- Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
- Dark Clouds Are Gathering For Cloud Stocks
- 3 Dividend Growers With Good 2023 Growth Prospects
- 免費獲取StockNews.com關於Prime Medicine(PRME)的研究報告
- 放寬Covid規則會降低中國電動汽車製造商蔚來的風險嗎?
- 聖誕老人拉力賽?以下是需要發生的事情
- Cosmos Holdings可能是具有短期風險的長期買入
- 烏雲雲集,雲股雲集
- 3個具有良好2023年增長前景的股息增長者
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
接受《頂級醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Prime Medicine和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。